Alzheimer'
Conditions
Interventions
PET (tau and beta-amyloid), MRI, Neuropsychological test, blood test
PET (tau and beta-amyloid), MRI, Neuropsychological test, blood test
PET (tau and beta-amyloid), MRI, Neuropsychological test, bloo
Sponsors
Nippon Medical School
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects who have the ability to provide informed consent and adhere to the protocol. Normal controls: - Without past or current history of cognitive dysfunction - Without past or current history of disease and injury that influences the central nervous system - Mini-Mental State Exam score is 28 or more Alzheimer's disease: - Subject who meet the diagnostic criteria of Alzheimer's disease on International classification of Diseases 10th revision - Informed consents are obtained from patients and one of their family members Psychotic disroders: - Subject who meet the diagnostic criteria of F2 on International classification of Diseases 10th revision Mood disorders: - Subject who meet the diagnostic criteria of F3 on International classification of Diseases 10th revision Brain injury: Subjects with past history of traumatic brain injury Epilepsy: Subjects with past history of seizure and with electroencephalogram abnormality
Exclusion criteria
Exclusion criteria: - With past or current history of serious medical illness - With past or current history of severe liver disease, kidney disease, heart disease, allergy, or severe drug allergy - Subjects who has possibility of pregnancy or is breast-feeding - Subjects who has been exposed to radiation by job-related exposure or therapy in one year exceeding 15mSv - Subjects who received contrast or radioactive agent within two days of the examination. - Subjects who scheduled receiving contrast or radioactive agent the day after the examination. - Subjects who are judged as not suitable for participation in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Degree of accumulation and distribution of tau protein in brain. | — |
Secondary
| Measure | Time frame |
|---|---|
| Degree of accumulation and distribution of beta-amyloid in brain neuropsychiatrci examination clinical symptoms morphometric MRI functional MRI blood test | — |
Countries
Japan
Contacts
Public ContactAmane Tateno
Nippon Medical School Department of Neuropsychiatry
Outcome results
None listed